Swedish Orphan Biovitrum (Sobi) has agreed a $1.7 billion merger deal to acquire CTI BioPharma and its recently-approved Vonjo drug for people with blood cancer myelofibrosis and severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback